Short Interest in OmniAb, Inc. (NASDAQ:OABIW) Decreases By 42.4%

OmniAb, Inc. (NASDAQ:OABIW) was the target of a large drop in short interest in the month of August. As of August 31st, there was short interest totaling 10,640 shares, a drop of 42.4% from the August 15th total of 18,488 shares. Based on an average daily trading volume, of 46,171 shares, the days-to-cover ratio is currently 0.2 days.

OmniAb Stock Performance

NASDAQ:OABIW traded down $0.11 during trading hours on Thursday, hitting $0.26. The company had a trading volume of 1,790 shares, compared to its average volume of 17,180. The stock has a 50-day moving average price of $0.17 and a 200 day moving average price of $0.12. OmniAb has a 52 week low of $0.04 and a 52 week high of $0.42.

OmniAb Company Profile

OmniAb, Inc is a clinical?stage biotechnology company specializing in the discovery and optimization of therapeutic antibodies. The company leverages a broad suite of proprietary platform technologies designed to accelerate antibody generation, characterization, and engineering. By integrating advanced immunization methods with high?throughput screening and bioinformatics, OmniAb aims to streamline the development of next?generation biologics across a range of disease areas.

At the core of OmniAb’s offering are its transgenic animal platforms, which have been engineered to produce fully human antibodies, and its complementary in vitro display and single?cell screening capabilities.